Biagio Ricciuti

ES-SCLC 5-year survival outcomes inIMpower133 and IMbrella study

Katsuaki Maehara, Director of Medical Education Colleagues, shared a post on X, about recent paper published in Lung Cancer Journal:

“ES-SCLC (Extensive Stage Small Cell Lung Cancer)

  • 5-year survival outcomes inIMpower133 and
    IMbrella a extension study.
  • 5-year OS rate 12% “

Five-year survival in patients with extensive-stage small cell lung cancer treated with atezolizumab in the Phase III IMpower133 study and the Phase III IMbrella a extension study

Authors: Martin Reck, Rafal Dziadziuszko, Shunichi Sugawara, Steven Kao, Maximilian Hochmair, Florian Huemer, Gilberto de Castro, Libor Havel, Reyes Bernabé Caro, György Losonczy, Jong-Seok Lee, Dariusz M. Kowalski, Zoran Andric, Raffaele Califano, Andrea Veatch, Gregory Gerstner, Marta Batus, Stefanie Morris, Monika Kaul, Vaikunth Cuchelkar, Huafei Li, Bradford J. Danner, Barzin Y. Nabet and Stephen V. Liu

ES-SCLC 5-year survival outcomes inIMpower133 and IMbrella study

Source: Katsuaki Maehara/X

Andrea Veatch Barzin Y. Nabet Bradford J. Danner cancer cell lung cancer Dariusz M. Kowalski Florian Huemer Gilberto de Castro Gregory Gerstner György Losonczy Huafei Li IMbrella inIMpower133 Jong-Seok Lee Katsuaki Maehara Libor Havel Lung Cancer Journal Marta Batus Martin Reck Maximilian Hochmair Medical Education Colleagues Monika Kaul OncoDaily Oncology Rafal Dziadziuszko Raffaele Califano Reyes Bernabé Caro SCLC Shunichi Sugawara Stefanie Morris Stephen V Liu Steven Kao Vaikunth Cuchelkar Zoran Andric